Advertisement

Topics

Amgen Gets Positive CHMP Opinion To Expand Use Of Nplate In Pediatric Patients

07:43 EST 10 Nov 2017 | RTTNews

Amgen Inc. (AMGN) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for Nplate, or romiplostim, to include the treatment of chronic immune (idiopathic) thrombocytopenic purpura or ITP for patients one year of age and older who are refractory to other treatments such as corticosteroids and immunoglobulins.

Original Article: Amgen Gets Positive CHMP Opinion To Expand Use Of Nplate In Pediatric Patients

NEXT ARTICLE

More From BioPortfolio on "Amgen Gets Positive CHMP Opinion To Expand Use Of Nplate In Pediatric Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...